The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUND
Although a wealth of efficacy and safety data is available for many tyrosine kinase inhibitors used in chronic myeloid leukemia (CML), there is a dearth of information on their impact on patients' health‐related quality of life (HRQOL). The primary objective of this study was to evaluate HRQOL and fatigue outcomes in patients with CML receiving first‐line therapy with nilotinib.
METHODS...
BACKGROUND
Biomarker‐guided clinical trials are increasingly common in metastatic urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue is not available are not eligible. Technological advancements in sequencing have made cell‐free circulating DNA (cfDNA) next‐generation sequencing (NGS) readily available in the clinic. The objective of the current study was to determine whether...
BACKGROUND
Cutaneous squamous cell carcinoma (CSCC) is a very common malignancy in which most patients present with localized disease. Recurrent and metastatic disease is rare, and there is no standard therapy. These tumors frequently overexpress the epidermal growth factor receptor (EGFR). We conducted a phase 2 trial to determine the response rate to therapy with erlotinib, an EGFR tyrosine kinase...
BACKGROUND
The Richmond Agitation‐Sedation Scale (RASS) is commonly used to assess psychomotor activity; however, to the authors' knowledge, its minimal clinically important difference (MCID) has not been determined to date. The objective of the current study was to identify the MCID for RASS using 2 anchor‐based approaches.
METHODS
The current study was a secondary analysis of a randomized controlled...
BACKGROUND
Despite recent advances in allogeneic hematopoietic stem cell transplantation (AHSCT), the outcome of patients who have acute myeloid leukemia (AML) with a complex karyotype (CK) remains poor. The objective of this study was to identify prognostic factors associated with post‐transplantation survival in a large cohort of patients with CK AML.
METHODS
In total, data on 1342 consecutively...
BACKGROUND
To the authors' knowledge, social network status in adolescent and young adult (AYA) cancer survivors has not been adequately studied to date. The authors developed and validated a functional social network index (FSNI) for AYA survivors, and compared its performance with that of 2 traditional indices (density and betweenness centrality).
METHODS
A total of 102 AYA survivors and 102...
BACKGROUND
T‐cell–depleted, haploidentical transplantations (haplos) are commonly offered to patients who have high‐risk, acute leukemia in the absence of a human leukocyte antigen (HLA) full‐matched donor.
METHODS
To determine the effect of transplantation period, the authors divided 308 adults with de novo, acute leukemia who underwent T‐cell–depleted haplo from 2005 to 2015 into 2 groups, according...
BACKGROUND
Epidermal growth factor receptor (EGFR) alterations are associated with multiple cancers. Current EGFR‐directed therapies have led to increased efficacy but are associated with specific side effects. The antibody‐drug conjugate depatuxizumab mafodotin (depatux‐m) targets EGFR with a monoclonal antibody linked to a cytotoxin, and is highly tumor‐specific.
METHODS
This phase 1/2 study...
BACKGROUND
The current study was performed to describe patient characteristics, treatment patterns, survival, health care resource use (HRU), and costs among older women in the United States with advanced (American Joint Committee on Cancer stage III/IV) triple‐negative breast cancer (TNBC) in the Surveillance, Epidemiology, and End Results (SEER)‐Medicare database.
METHODS
Women who were aged...
BACKGROUND
Although breast cancer often is perceived to be indolent in older women, breast cancer outcomes in the oldest patients are variable. In the current study, the authors examined breast cancer‐specific death by age, stage, and disease subtype in a large, population‐based cohort.
METHODS
Using Surveillance, Epidemiology, and End Results data, a total of 486,118 women diagnosed with American...
BACKGROUND
Cancer care and end‐of‐life (EOL) care contribute substantially to health care expenditures. Outside of clinical trials, to our knowledge there exists no standardized protocol to monitor disease progression in men with metastatic prostate cancer (mPCa). The objective of the current study was to evaluate the factors and outcomes associated with increased imaging and serum prostate‐specific...
Advances in cancer immunotherapy and a growing body of research have focused on the role of the antitumor response in breast cancer. Triple‐negative breast cancer (TNBC) is the most immunogenic breast cancer subtype, and there is strong evidence that tumor‐infiltrating lymphocytes in TNBC have prognostic value and are associated with clinical outcome and improved survival. Evading antitumor immunity...
BACKGROUND
The increasing incidence of oropharyngeal squamous cell cancer (OPSCC) is well established. However, up‐to‐date incidence estimates and trends for head and neck squamous cell cancers (HNSCCs) overall, including major anatomic sites, and nonoropharyngeal (non‐OP) HNSCCs by sex, race, and age in the United States are not well described.
METHODS
A retrospective analysis of incident HNSCCs...
BACKGROUND
Inotuzumab ozogamicin (InO), an anti‐CD22 antibody‐calicheamicin conjugate, demonstrated superior clinical activity versus standard‐of‐care (SOC) chemotherapies for relapsed/refractory B‐cell acute lymphoblastic leukemia in the phase 3 randomized controlled INO‐VATE trial. The authors assessed patient‐reported outcomes (PROs) from that study.
METHODS
Patients were randomized to receive...
BACKGROUND
Although cancer drug shortages are a persistent problem in oncology, little is known about the awareness and perspectives of the US population with respect to shortages.
METHODS
In 2016, we administered a 13‐item cross‐sectional survey to 420 respondents who were randomly selected from an online, probability‐based sample demographically representative of the adult US population with...
BACKGROUND
To explore the clinical efficacy of traditional herbal medicine (THM) in the prevention of disease recurrence of small hepatocellular carcinoma after surgery, a prospective randomized controlled study was conducted between October 2006 and May 2010. The results indicated that THM prevented the recurrence of SHCC with an efficacy that was superior to that of transarterial chemoembolization...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.